Search Results
Dec 08, 2025, 08:30 ET SpartanNash Celebrates Expansion of Supermercado Nuestra Familia Banner, Company Footprint with Topeka Grand Opening
goods, including within our private label portfolio. C&S operates more than 200 corporate-run grocery stores primarily under the banners: D&W® Fresh Market, Grand Union, Family Fare®, Martin's Super Markets and Piggly Wiggly®. C&S is deeply committed to corporate
More news about: SpartanNash
Dec 08, 2025, 08:21 ET DEEPX- Announces Ultra-Efficient AI Video Analytics Solution Based on AmpereOne® Platform
power efficiency is equally disruptive. Whereas traditional CPU + GPU servers routinely exceed 1,200W to achieve similar workloads, the DEEPX platform maintains total system power between 400W and 750W, depending on configuration. This results in a step-change reduction in operational expenses for
More news about: DEEPX
Dec 08, 2025, 08:18 ET DEEPX- Announces Ultra-Efficient AI Video Analytics Solution Based on AmpereOne® Platform
power efficiency is equally disruptive. Whereas traditional CPU + GPU servers routinely exceed 1,200W to achieve similar workloads, the DEEPX platform maintains total system power between 400W and 750W, depending on configuration. This results in a step-change reduction in operational expenses for
More news about: DEEPX
Dec 08, 2025, 08:03 ET Grace and Molecule.one to Transform Peptide Building Block Synthesis with AI and Automation
W. R. Grace & Co. (Grace), a Standard Industries company and leading global supplier of specialty chemicals and solutions that enable industries
More news about: W. R. Grace
Dec 08, 2025, 08:00 ET STUB INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that StubHub Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
More news about: Robbins Geller Rudman & Dowd LLP
Dec 08, 2025, 07:28 ET BingX wprowadza duże ulepszenie copy tradingu, osiągając 1,3 miliarda skopiowanych zleceń
powiedziała Vivien Lin, Chief Product Officer w BingX. „Copy trading to obszar, w którym BingX naprawdę wyróżnia się w branży. Ta aktualizacja jest efektem lat opinii użytkowników oraz innowacji – czyniąc proces bardziej przejrzystym,
More news about: BingX
Dec 08, 2025, 07:10 ET KLAR INVESTIGATION ALERT: Investigation Launched into Klarna Group plc, Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm
offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900
More news about: Robbins Geller Rudman & Dowd LLP
Dec 08, 2025, 07:01 ET Wystawa Blokees na targach CCXP25 w Brazylii: światowa premiera nowego produktu z serii Rycerzy Zodiaku
intelektualnej, takie jak Transformers, również cieszyły się liczną i wierną rzeszą fanów w Brazylii. Podczas CCXP zadebiutowało prawie 10 nowych produktów firmy Blokees, w tym Transformers HERO 5 dla konsumentów w wieku od 6 do 16 lat oraz seria Legend dla konsumentów powyżej 16 roku życia.Podczas
More news about: Blokees
Dec 08, 2025, 07:00 ET Secure the Limited Time Offered 2025-2026 ezPaycheck Bundle!
new Efile 941 add on feature. W2 and W3 form processing (Copy A preprinted form required for W2 and W3)PDF feature available at no additional costSupports multiple differentials pay rates such as: hourly,
More news about: Halfpricesoft.com
Dec 08, 2025, 07:00 ET WindRose Health Investors Makes Strategic Investment in Stellus Rx
are excited to partner with Tony and the Stellus Rx team to scale a model that combines clinical excellence with value-based outcomes."Robert W. Baird & Co. acted as financial advisor to Stellus Rx. Goodwin Procter LLP served as legal advisor to Stellus Rx. McDermott Will & Schulte LLP
More news about: WindRose Health Investors
Dec 08, 2025, 07:00 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduced countable motor seizure frequency in CDKL5 deficiency disorder
2022;9(12):1806.6 Jakimiec M, et al. CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy. Brain Sci. 2020;10(2):107.7 Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.8 Leonard
More news about: UCB
Dec 08, 2025, 06:01 ET Protective Clothing Market worth $15.06 billion by 2030 - Exclusive Report by MarketsandMarkets™
Protective Industrial Products, Inc. (US), TenCate Protective Fabrics (Netherlands), PBI Performance Products, Inc. (US), Sioen Industries NV (Belgium), W. L. Gore & Associates, Inc. (US) and others.Get access to the latest updates on
More news about: MarketsandMarkets
Dec 08, 2025, 05:25 ET Voranigo® (vorasidenib) de Servier remporte le Prix Galien dans plusieurs pays
Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma.
More news about: Servier
Dec 08, 2025, 05:14 ET Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma.
More news about: Servier
Dec 08, 2025, 05:05 ET Servier's Voranigo® (vorasidenib) Receives Prix Galien Awards Across Multiple Regions
Blumenthal, D. T., Touat, M., Peters, K. B., Clarke, J., Mendez, J., Yust-Katz, S., Welsh, L., Mason, W. P., Ducray, F., Umemura, Y., Nabors, B., Holdhoff, M., Hottinger, A. F., Arakawa, Y., Sepulveda, J. M., Wick, W., Soffietti, R., … Cloughesy, T. F. (2023). Vorasidenib in idh1- or IDH2-mutant low-grade glioma.
More news about: Servier
Dec 08, 2025, 04:00 ET Nagrody Huawei AppGallery Editors' Choice Awards 2025 to święto innowacji i doskonałości w dziedzinie aplikacji i gier mobilnych
W szóstej edycji wyróżniono wybitne tytuły z bogatej puli globalnych i lokalnych twórców wyłonione w ramach rygorystycznego procesu oceny liczby pobrań, innowacyjności, opowiadania historii, projektu,
More news about: Huawei Consumer Business Group
Dec 08, 2025, 02:00 ET DCK zostaje wyłącznym partnerem CFMOTO Thunder Racing Team w zakresie elektronarzędzi
Racing Team z siedzibą na Litwie to jeden z wiodących zespołów rajdowych w Europie. Osiągnął on znakomite wyniki w sezonie 2025, w tym najwyższe miejsca w najważniejszych międzynarodowych zawodach, takich jak Abu Dhabi Desert Challenge w kategorii quadów. Dzięki doskonałym wynikom i reputacji zespołu, który
More news about: DongCheng
Dec 08, 2025, 01:32 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
2022;9(12):1806.[6] Jakimiec M, et al. CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy. Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla®
More news about: UCB
Dec 08, 2025, 01:28 ET UCB presents positive results from GEMZ phase 3 study at AES showing fenfluramine significantly reduces countable motor seizure frequency in CDKL5 Deficiency Disorder
2022;9(12):1806.[6] Jakimiec M, et al. CDKL5 Deficiency Disorder—A Complex Epileptic Encephalopathy. Brain Sci. 2020;10(2):107.[7] Hong W, et al. CDKL5 Deficiency Disorder-Related Epilepsy: A Review of Current and Emerging Treatment. CNS Drugs. 2022;36(6):591–604.[8] Fintepla®
More news about: UCB
Dec 08, 2025, 01:00 ET Huawei nagradza czołowych tureckich deweloperów i projektantów podczas gali nagród w Stambule
/PRNewswire/ -- HUAWEI Mobile Services zorganizował dziś w Stambule wydarzenie Türkiye Developer & Designer Awards, podczas którego uhonorowano najbardziej innowacyjnych twórców aplikacji oraz projektantów tarcz zegarków w Turcji za ich wyjątkowy wkład w rozwój ekosystemu urządzeń do noszenia Huawei.
More news about: Huawei Consumer Business Group
Dec 07, 2025, 21:22 ET JOYROOM PODIX: The First Tri-Magnetic 140W 5-in-1 Charging Station
announces its latest all-in-one charging innovation: the JOYROOM PODIX, the world's first Tri-Magnetic 140W 5-in-1 GaN Charging Station. Engineered as a powerful 140W 5-Port Desktop GaN Charger, PODIX is designed to upgrade power delivery, declutter the workspace, and redefine the
More news about: JOYROOM
Dec 07, 2025, 20:02 ET ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
(QW). For patients who have received continuous treatment for ≥6 months and achieved partial response (PR) or better for ≥2 months could switch to Q2W as maintenance. To reduce the risk of cytokine release syndrome (CRS), 1 to 3 priming doses were included in the study design.A total of 39 patients
More news about: Innovent Biologics
Dec 07, 2025, 18:02 ET Matthews International Provides Update on Actions to Create Shareholder Value and Addresses Director Nominations
Garcia-Tunon, Joseph C. Bartolacci, Katherine E. Dietze, Terry L. Dunlap, Lillian D. Etzkorn, Morgan K. O'Brien, Thomas Gebhardt, J. Michael Nauman, Aleta W. Richards, David A. Schawk, Francis S. Wlodarczyk and Brian D. Walters. Certain information about the compensation of the Company's named executive officers
More news about: Matthews International Corporation
Dec 07, 2025, 16:30 ET Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
ReferencesMato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892-901. doi:10.1016/S0140-6736(21)00224-5Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J
More news about: Eli Lilly and Company
Dec 07, 2025, 07:30 ET Studies Point to a Growing Role for New Therapies and Immunotherapies in Treating Blood Cancers
Oncology.Jennifer Woyach, MD, of The Ohio State University College of Medicine, will present this study on Sunday, December 7, 2025, at 5:30 p.m. Eastern time in W224ABEF of the Orange County Convention Center. New Findings Support a Chemo-Free Approach for Treating Ph+ ALL
More news about: American Society of Hematology